Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV
Kumari G. Lokugamage, Adam Hage, Maren de Vries, Ana M. Valero-Jimenez, Craig Schindewolf, Meike Dittmann, Ricardo Rajsbaum, Vineet D. Menachery
Abstract
With the ongoing outbreak of COVID-19, differences between SARS-CoV-2 and the original SARS-CoV could be leveraged to inform disease progression and eventual treatment options. In addition, these findings could have key implications for animal model development as well as further research into how SARS-CoV-2 modulates the type I IFN response early during infection.
Topics & Concepts
BiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakOutbreakInterferon type IBetacoronavirusInterferonSars virusCoronavirus InfectionsCoronavirusImmunologyDiseaseInfectious disease (medical specialty)MedicinePathologySARS-CoV-2 and COVID-19 Researchinterferon and immune responsesCOVID-19 Clinical Research Studies